Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerType 2 Diabetes (T2D)Pharmacological Treatments
Research Summary
Analyzed using Evidence Intelligence™
Switching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristics
Last updated May 30, 2026
Key finding
Switching to tirzepatide from dulaglutide resulted in consistently greater HbA1c and weight reductions versus dulaglutide dose escalation across all baseline subgroups in adults with T2D.
This subgroup analysis of SURPASS-SWITCH found that switching to tirzepatide from dulaglutide provided greater improvements in blood sugar control and weight loss compared to escalating dulaglutide dose, with consistent benefits across all patient groups including different ages, baseline HbA1c levels, diabetes duration, BMI categories, and ethnicities.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
High
Study type
Randomized Controlled Trials (RCTs)
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Switching to tirzepatide from dulaglutide resulted in consistently greater HbA1c and weight reductions versus dulaglutide dose escalation across all baseline subgroups in adults with T2D.
Published in
Journal Reference
Publication details and source links for this paper.
Violante-Ortiz R, Rose L, Sharma P, et al. Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. BMJ Open Diabetes Res Care. 2026;14(2):e005711. doi:10.1136/bmjdrc-2025-005711
Main Effects
HbA1c ↓ greater with tirzepatide vs dulaglutide across all subgroups (difference -0.7% to -1.2%)
Body weight ↓ greater with tirzepatide vs dulaglutide across all subgroups (difference -5.7 to -8.6 kg)
Adverse events rates similar between treatments, with GI symptoms (nausea, diarrhea) most common
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide, Tirzepatide and Body weight, HbA1c, Adverse events incidence, and 1 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- Body weight
- HbA1c
- Adverse events incidence
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
High contributionHigh confidenceNetwork score: 80
3
Related topics
6
Evidence pairs
362
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Uses a randomized study design signal
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerAdverse events incidence
Tirzepatide → Adverse events incidence
Tirzepatide → Adverse events incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 8 studies
Add to Evidence TrackerGastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 9 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Tirzepatide switching provided consistent HbA1c and weight reductions regardless of age, sex, ethnicity, diabetes duration, BMI, baseline HbA1c, or dulaglutide dose/duration
- HbA1c reductions were numerically larger in participants with higher baseline HbA1c (>8.5%) and lower BMI (<27 kg/m²)
- Weight reduction was significantly greater in non-Hispanic/Latino participants compared to Hispanic/Latino participants
Who this applies to
Adults with type 2 diabetes on dulaglutide 0.75mg or 1.5mg with HbA1c 7.0-9.5%
Keep in Mind
Results represent a subgroup analysis; interpret with caution given multiple comparisons
Between the Lines
- Open-label study design may introduce bias
- Limited sample sizes in some subgroups (e.g., BMI <27 kg/m²: n=27)
- Study not powered for subgroup analyses or safety comparisons
- Multiple subgroup testing increases risk of false-positive findings
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 9 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 8 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
9 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
9 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
8 studies
outcome_hubMeasures Body Weight as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
9 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
8 results
All studies on Tirzepatide
Intervention: Tirzepatide
9 results
All studies measuring HbA1c
Outcome: HbA1c
9 results
All studies measuring Body weight
Outcome: Body weight
8 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 84.4 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.6 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 27 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
GLP-1 Receptor Agonists may worsen Gastrointestinal Adverse Events or be associated with harm.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Does Tirzepatide affect adverse events incidence?
Emerging Evidence
Current evidence does not show a clear benefit of Tirzepatide for Adverse events incidence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Adverse events incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesTirzepatide improves glycemic control and weight loss in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.